Table 1 Patients characteristics at allogeneic HSCT
From: Tregs and GvHD prevention by extracorporeal photopheresis: observations from a clinical trial
| Median age, years (range) | 62 (36–67) |
| Gender M/F, number (%) | 5 (42)/7 (58) |
| Diagnosis, number (%) | |
| Acute Myeloid Leukemia | 6 (50) |
| Non-Hodgkin´s Lymphoma | 3 (25) |
| Myelodysplastic Syndrome | 2 (17) |
| Hodgkin´s Lymphoma | 1 (8) |
| Disease status at HSCT, number (%) | |
| CR1 | 4 (33) |
| CR2 | 6 (50) |
| PR | 2 (17) |
| Hematopoietic stem cell donor, number (%) | |
| HLA-identical sibling | 6 (50) |
| Unrelated donor | 6 (50) |
| Median CD34 + infused, 106/kg (range) | 6.47 (4.90–10.41) |
| Median CD3 + infused, 108/kg (range) | 9.92 (6.23–19.61) |
| Median ECP duration, months (range) | 5 (1–12) |